FDA recall record

Teva Pharmaceuticals USA Montelukast Sodium Oral Granules USP, 4 mg recall — FDA D-0510-2023

Failed Impurities/Degradation Specifications: failed impurities for Sulphoxide and Impurity A.

Class IIIclassification
D-0510-2023official record ID
Apr 12, 2023report date

Recall record at a glance

Official recordD-0510-2023
CategoryDrug Recalls
ClassificationClass III
FDA record statusTerminated
Recalling firmTeva Pharmaceuticals USA Inc.
Report dateApr 12, 2023
Recall initiation dateMar 27, 2023
Quantity3,772 cartons
LocationParsippany, NJ, United States

Official product description

Montelukast Sodium Oral Granules USP, 4 mg, packaged in a carton containing 30 packets, Rx only, Distributed By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, Carton NDC 0093-7487-56, Packet NDC 0093-7487-19

Why the product was recalled

Failed Impurities/Degradation Specifications: failed impurities for Sulphoxide and Impurity A.

Distribution information

USA Nationwide

How to read the classification

FDA Class III generally covers situations in which use of or exposure to the product is not likely to cause adverse health consequences. The classification displayed here is taken from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.

DrugApr 29, 2026

Claravis recall — FDA D-0521-2026

Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin

Class IIFDA: OngoingTeva Pharmaceuticals USA, Inc